Advertisement
Screener

INSMED INC (INSM) Net Margin

INSMED Inc Net Margin

Net margin is the percentage of revenue a company keeps as profit after every expense and tax. It is net income divided by revenue, and the table shows both amounts beside the percentage. A higher net margin means more of each sales dollar reaches the bottom line. One-time gains, write-downs and tax items pass through net income, so a single period's net margin can move for reasons unrelated to the underlying business. Quarterly and annual points each use the amounts filed for that same period, so a single quarter can swing with the seasons.

  • INSMED Inc net margin for the quarter ending 2026-06-30 was -3.11%, a change of 296.37% year-over-year.
  • INSMED Inc net margin for the quarter ending 2026-03-31 was -53.46%, a change of 222.96% year-over-year.
  • INSMED Inc net margin for the quarter ending 2025-12-31 was -124.50%, a change of 101.03% year-over-year.
  • INSMED Inc net margin for the quarter ending 2025-09-30 was -259.95%, a change of -23.91% year-over-year.
  • INSMED Inc net margin for fiscal 2025 was -210.54%, a change of 40.70% from fiscal 2024.
  • INSMED Inc net margin for fiscal 2024 was -251.24%, a change of -5.65% from fiscal 2023.
  • INSMED Inc net margin for fiscal 2023 was -245.59%, a change of -49.33% from fiscal 2022.
  • INSMED Inc net margin for fiscal 2022 was -196.26%, a change of 34.38% from fiscal 2021.
Available history
2009-12-31 to 2026-06-30
Data captured

Historical Net Margin

DateNet MarginNet incomeRevenue
2026-06-30-3.11%-$13.24M$425.49M
2026-03-31-53.46%-$163.56M$305.96M
2025-12-31-124.50%-$328.49M$263.84M
2025-09-30-259.95%-$370.02M$142.34M
2025-06-30-299.48%-$321.69M$107.42M
2025-03-31-276.42%-$256.58M$92.82M
2024-12-31-225.53%-$235.55M$104.44M
2024-09-30-236.04%-$220.52M$93.43M
2024-06-30-332.75%-$300.61M$90.34M
2024-03-31-208.07%-$157.09M$75.5M
2023-12-31-222.31%-$186.06M$83.69M
2023-09-30-201.00%-$158.93M$79.07M
2023-06-30-316.99%-$244.81M$77.23M
2023-03-31-244.98%-$159.76M$65.21M
2022-12-31-270.02%-$160.12M$59.3M
2022-09-30-193.63%-$131.15M$67.73M
2022-06-30-146.65%-$95.65M$65.22M
2022-03-31-178.17%-$94.62M$53.11M
2021-12-31-201.30%-$112.98M$56.12M
2021-09-30-241.06%-$112.71M$46.76M
2021-06-30-258.61%-$117.32M$45.37M
2021-03-31-227.88%-$91.64M$40.21M
2020-12-31-246.80%-$102.21M$41.42M
2020-09-30-145.86%-$63.66M$43.64M
2020-06-30-145.56%-$61.85M$42.5M
2020-03-31-180.04%-$66.36M$36.86M
2019-12-31-115.93%-$52.99M$45.71M
2019-09-30-156.06%-$60.68M$38.89M
2019-06-30-221.92%-$66.51M$29.97M
2019-03-31-338.57%-$74.15M$21.9M
2018-12-31-931.09%-$91.57M$9.84M
2011-12-31-581.75%-$8.16M$1.4M
2011-09-30-7951.95%-$34.59M$435,000.00
2011-06-30-1024.23%-$10.02M$978,000.00
2011-03-31-430.61%-$6.89M$1.6M
2010-12-31-442.39%-$5.84M$1.32M
2010-09-30-18.26%-$330,000.00$1.81M
2010-06-30-20.28%-$378,000.00$1.86M

Annual Net Margin

DateNet MarginNet incomeRevenue
2025-12-31-210.54%-$1.28B$606.42M
2024-12-31-251.24%-$913.77M$363.71M
2023-12-31-245.59%-$749.57M$305.21M
2022-12-31-196.26%-$481.53M$245.36M
2021-12-31-230.63%-$434.65M$188.46M
2020-12-31-178.87%-$294.09M$164.41M
2019-12-31-186.37%-$254.34M$136.47M
2018-12-31-3297.17%-$324.28M$9.84M
2013-12-31-487.59%-$56.07M$11.5M
2011-12-31-1350.78%-$59.66M$4.42M
2010-12-31-92.96%-$6.43M$6.92M
2009-12-311140.94%$118.35M$10.37M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Zoetis Inc. (ZTS)United States$29.045B11.38
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10